Malaysia
National Pharmaceutical Regulatory Agency (NPRA)
Malaysia regulates pharmaceutical products through the National Pharmaceutical Regulatory Agency (NPRA, Bahagian Regulatori Farmasi Negara), a division of the Ministry of Health. The legal framework is the Sale of Drugs Act 1952 and the Control of Drugs and Cosmetics Regulations 1984 (CDCR 1984), with subordinate guidance consolidated in the Drug Registration Guidance Document (DRGD), 3rd Edition (currently 11th Revision, January 2026). Statutory registration decisions are made by the Drug Control Authority (DCA, Pihak Berkuasa Kawalan Dadah). NPRA operates Full, Abridged, Verification and Facilitated Registration Pathways (FRP). The FRP enables expedited review for products approved by reference regulatory agencies (RRAs) — US FDA, EMA, MHRA, Health Canada, TGA, PMDA, Swissmedic and HSA Singapore. Malaysia is a PIC/S member (since 2002) and an active ASEAN PPWG participant implementing ACTD/ACTR. Public-sector reimbursement is anchored on the Ministry of Health Medicines Formulary (MOHMF), with HTA support from MaHTAS (Malaysian Health Technology Assessment Section). The MyHEALTH cost-effectiveness threshold and managed-access agreements increasingly shape access for high-cost therapies.
About the authority
NPRA is the regulatory arm of the Pharmaceutical Services Programme, Ministry of Health Malaysia. It administers product registration, GMP/GDP inspections, licensing, lot release for biologicals and vaccines, and pharmacovigilance. Statutory registration decisions are made by the Drug Control Authority (DCA), supported by NPRA evaluation divisions and expert advisory committees. NPRA has been a PIC/S member since 2002 and an ICH Observer.
Reliance & recognition
NPRA recognises Reference Regulatory Agencies (RRAs) under the Facilitated Registration Pathway (FRP) and operates Verification Review for products with high-quality RRA assessment reports. ASEAN harmonisation (ACTD/ACTR, MRA on GMP) further supports cross-recognition within ASEAN.
Compare Malaysia side-by-side
Benchmark timelines, fees and pathway requirements against another market.
Other Asia-Pacific markets
Same structure. Same source-citation standard.